Here are the 10-Q quarterly reports from Cardio Diagnostics Holdings Inc. Warrant (CDIOW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CDIOW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDIOW filings page.
Cardio Diagnostics Holdings, Inc. reported third-quarter 2026 revenue of $3,590, compared with $2,855 a year earlier, while net loss was $1,732,331 versus $1,714,536. For the nine months, revenue was $11,630 versus $11,270 and net loss was $5,021,957 versus $5,032,799.
Cash was $3,942,882 at September 30, 2026, and operating activities used $4,420,474 in cash in the first nine months. The company said existing funds and its ATM offering are expected to fund activities over the next 12 months; it expects to need additional equity and/or debt to fund operations beyond that period. As of November 6, 2026, it had sold 2,251,181 shares under the ATM and could sell up to $5,298,889 more through Craig-Hallum.
Cardio said its high-complexity CLIA lab began testing patient samples from all states except New York, pending that state's license. Atlas Healthcare Physicians began covering Epi+Gen CHD and PrecisionCHD in May 2026, subject to prior authorization; Cardio said it secured CMS gapfill payment rates of $854 per test for both. In India, it reported engaging physicians to educate them about PrecisionCHD.
Cardio Diagnostics Holdings develops AI‑driven blood tests for cardiovascular disease. For the quarter ended June 30, 2026, it generated revenue of $5,360 and incurred a net loss of $1,501,468, or $0.51 per share, on operating expenses of $1,503,507.
For the first six months of 2026, revenue was $8,040 with a net loss of $3,289,626. Cash was $5,586,697 at June 30, 2026, and stockholders’ equity totaled $7,426,283, against total liabilities of $499,780.
The company continues to fund operations primarily through equity, including $3,693,470 of net proceeds from at‑the‑market share sales in 2026. With 2,959,469 shares outstanding, management notes ongoing operating losses, modest revenue to date, and dependence on future capital raises and broader test adoption.
Cardio Diagnostics Holdings, Inc. reported a first-quarter 2026 net loss of $1,788,158 on very early-stage revenue of $2,680, reflecting continued investment ahead of broad commercialization. Operating expenses were $1,787,517, driven mainly by general and administrative costs, sales and marketing, and research and development.
Cash increased to $7,077,021 as of March 31, 2026, helped by $3,693,470 in net proceeds from at-the-market common stock sales, leaving stockholders’ equity at $8,903,399. The company continues to expand adoption of its AI-driven cardiovascular tests, build evidence, and rely on equity financing while acknowledging its disclosure controls were not effective.